MedDataX Logo

Ultrasound Enhanced Thrombolytic Therapy of Middle Cerebral Artery Occlusion

NCT ID: NCT00336596

Last Updated: 2007-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the present, randomized, controlled multicenter phase III trial is to investigate the safety and efficacy of continuous 1-hour insonation of occluded middle cerebral artery with 2 MHz TCCS in stroke patients treated with intravenous tissue plasminogen activator (t-PA) within 3 hours after symptom onset.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thrombolysis with intravenous(iv) tissue plasminogen activator (t-PA) is the only effective and approved therapy for acute ischemic stroke. The most frequent cause of ischemic stroke is thrombosis of the middle cerebral artery (MCA). Preliminary in vitro, animal and human studies suggest that ultrasound accelerates thrombolysis induced by t-PA, and recanalization of acute MCA occlusion due to thrombolysis is an independent predictor of good clinical outcome. Thus, insonation of an occluded MCA through the temporal bone in stroke patients who are treated with iv t-PA might enhance recanalization and improve clinical outcome. The present prospective, randomized, controlled multicenter pilot study will investigate the safety and efficacy of continuous 1-hour insonation of the occluded MCA with 2 MHz transcranial color duplex sonography in patients with ischemic stroke treated with iv t-PA within 3 hours after symptom onset. It is planned to randomize 400 patients in 6 Swiss centers during an enrolment period of 33 months with an individual follow up of 3 months. The study endpoints include safety and efficacy assessments. The primary safety endpoint is to determine the rate of symptomatic intracranial hemorrhage (ICH) in both treatment groups. The primary efficacy endpoint is to determine whether a good functional outcome (modified Rankin scale, mRs, score of 0-2) differs between both treatment groups. Secondary endpoints include (1) asymptomatic ICH occuring during or within the first 24-48 hours after t-PA infusion, (2) early clinical recovery by 10 or more National Institute of Health Stroke Scale (NIHSS) points or dramatic recovery (total NIHSS score of 3 or less) at 24-48 hours after t-PA infusion, (3) mean mRS score at 90 days after t-PA infusion, (4) death occuring during the study period, and (5) recanalization at 24-48 hours after t-PA infusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intracranial Embolism Thrombosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

middle cerebral artery occlusion intracranial embolism and thrombosis ultrasound enhanced thrombolysis Patients receiving iv thrombolytic therapy (t-PA)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transcranial ultrasound in patients treated with iv t-PA

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* acute ischemic stroke in the MCA territory according to clinical and cranial computed tomography (CT) or cranial MR imaging (MRI) findings
* patient undergoing iv thrombolysis with t-PA within 3 hours after stroke onset
* Occlusion of sphenoidal (M1) or insular (M2) segment of the MCA at CT (CTA), MR (MRA) or catheter (CA) angiography
* appropriate temporal bony window without echocontrast agents for insonation with TCCS
* full functional independence prior to present stroke (mRS 0-1), use of a cane for walking due to comorbid condition is acceptable
* written informed consent, signed and dated by the subject (or subject's authorized representative, if allowed by local laws) and by the person obtaining the consent, indicating agreement to comply with all protocol-specific procedures

Exclusion Criteria

* unconsciousness (more than 2 points on item 1a on NIHSS)
* history of intracranial hemorrhage, arteriovenous malformation or aneurysm
* severe cranio-cerebral trauma within the last 3 months
* symptoms of subarachnoidal hemorrhage
* time of symptom onset unclear
* large surgical intervention or trauma within the last 10 days
* expected survival below 90 days after iv t-PA treatment
* severe hepatic disease, esophageal varices, acute pancreatitis
* septic embolism, endocarditis, pericarditis after myocardial infarction
* pregnancy or childbirth within the last 30 days or nursing mothers
* history of hemorrhagic diathesis or coagulopathy
* untreatable increase of arterial blood pressure (\>185mmHg systolic, \>110mmHg diastolic)
* intracranial hemorrhage, arteriovenous malformations or aneurysm at brain imaging
* thrombocytes \<100'000 per microliter
* international normalized ratio (INR)\>1.7 or partial thromboplastin time (PTT) prolongated
* serum glucose \<2.7mmol/l or \>22.2mmol/l
* severe renal insufficiency or other contraindications against CT-contrast agents
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Swiss National Science Foundation

OTHER

Sponsor Role collaborator

University of Zurich

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ralf W Baumgartner, MD

Role: STUDY_CHAIR

University Hospital of Zurich, Department of Neurology, Zurich, Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kantonsspital Aarau, Department of Neurology

Aarau, , Switzerland

Site Status RECRUITING

University Hospital of Basel, Department of Neurology

Basel, , Switzerland

Site Status RECRUITING

University hospital of Bern, Department of Neurology

Bern, , Switzerland

Site Status RECRUITING

University Hospital of Geneva, Department of Neurology

Geneva, , Switzerland

Site Status RECRUITING

University Hospital of Lausanne, Department of Neurology

Lausanne, , Switzerland

Site Status RECRUITING

University Hospital of Zurich, Department of Neurology

Zurich, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ralf W Baumgartner, MD

Role: CONTACT

Phone: +41 1 255 56 86

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hansjörg Hungerbühler, MD

Role: primary

Stefan Engelter, MD

Role: primary

Marcel Arnold, MD

Role: primary

Roman Sztajzel, MD

Role: primary

Patrik Michel, MD

Role: primary

Ralf W Baumgartner, MD

Role: primary

Dimitrios Georgiadis, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-031/2004

Identifier Type: -

Identifier Source: org_study_id